RCBVmax from DSC Perfusion MRI as a Supportive Imaging Biomarker for Differentiating IDH-Mutant Astrocytomas and Oligodendroglioma
rCBVmax emerges as a potential imaging marker for differentiating oligodendrogliomas from astrocytomas. These findings can be explained by biological properties of oligodendrogliomas and thereby underscore the potential of advanced imaging techniques in non-invasive glioma classification. However, larger prospective studies are required to validate these results and standardize imaging protocols.
Authors
- Anja G. van der Kolk (ORCID: https://orcid.org/0000-0002-8267-8848)
- Dylan Jozef Hendrik Augustinus Henssen (ORCID: https://orcid.org/0000-0002-3915-3034)
- Manoj Mannil (ORCID: https://orcid.org/0000-0001-9335-9546)
- Christian Rubbert (ORCID: https://orcid.org/0000-0002-9461-1173)
- Manfred Musigmann
- Mathias Prokop (ORCID: https://orcid.org/0000-0001-8157-8055)
- Feraco Paola
- Marion Smits
- Frederick J. A. Meijer
Institutions
- Radboud University Nijmegen (NL)
- University of Trento (IT)
- Radboud University Medical Center (NL)
- Düsseldorf University Hospital (DE)
- University Hospital Münster (DE)
- University Hospital Leipzig (DE)
- Life Science Center Düsseldorf (Germany) (DE)
- Erasmus MC Cancer Institute (NL)
- Heinrich Heine University Düsseldorf (DE)
- Rotterdam University of Applied Sciences (NL)
- Leipzig University (DE)
Publication Details
- Journal
- Clinical Neuroradiology
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1007/s00062-026-01624-w
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00